|
Revenue Interest Purchase Agreement with PDL BioPharma, Inc.
(“PDL”) for aggregate of $20,800,000 with amounts
payable monthly at 9.95% of Net Revenues through September 2014;
and the greater of (i) 9.95% of product revenue or
(ii) specific quarterly amounts varying from approximately
$1.3 million to $2.5 million per quarter through September 2020.
The minimum annual payment amounts are as follows:
2014—$1,250,805, 2015—$6,781,440,
2016—$9,232,642, 2017 and 2018—$9,000,000,
2019—$9,063,000 and 2020—$6,939,000.
|
|
$ |
24,332,525 |
|
|
$ |
21,580,252 |
|